Treatment of lung cancer cells with phoyunnanin E decreases the levels of active AKT/FAK, integrin-mediated migration, and the expression of EMT markers such as N-cadherin, vimentin, snail, and slug [224]. Here, PTK2 is linked to lung carcinoma.